• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients.

作者信息

Mangaonkar Abhishek A, Langer Kimberly J, Lasho Terra L, Finke Christy, Litzow Mark R, Hogan William J, Shah Mithun V, Go Ronald S, Bartoo Gabriel, Kutzke Jade, McCullough Kristen B, Koster Matthew, Samec Matthew, Warrington Kenneth J, Reichard Kaaren K, Olteanu Horatiu, Riwes Mary, Patnaik Mrinal M, Alkhateeb Hassan B

机构信息

Dvision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

出版信息

Am J Hematol. 2023 Feb;98(2):E28-E31. doi: 10.1002/ajh.26786. Epub 2022 Dec 1.

DOI:10.1002/ajh.26786
PMID:36403135
Abstract
摘要

相似文献

1
Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients.VEXAS综合征中减低强度预处理异基因造血干细胞移植：来自一系列前瞻性患者的数据
Am J Hematol. 2023 Feb;98(2):E28-E31. doi: 10.1002/ajh.26786. Epub 2022 Dec 1.
2
Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.减低强度预处理异基因造血移植后高危急性髓系白血病和骨髓增生异常综合征的持续缓解：慢性移植物抗宿主病是改善生存的最强因素。
J Clin Oncol. 2008 Feb 1;26(4):577-84. doi: 10.1200/JCO.2007.11.1641. Epub 2007 Dec 17.
3
Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.三氧化二砷联合全反式维甲酸治疗急性早幼粒细胞白血病 105 例临床分析
Haematologica. 2011 Sep;96(9):1344-50. doi: 10.3324/haematol.2011.043810. Epub 2011 Jun 9.
4
Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients.慢性移植物抗宿主病对异基因造血细胞移植后初发骨髓增生异常综合征患者结局的积极影响：一项单中心 115 例患者分析。
Eur J Haematol. 2014 Feb;92(2):137-46. doi: 10.1111/ejh.12214. Epub 2013 Nov 9.
5
Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.异基因造血细胞移植治疗高危急性髓系白血病和骨髓增生异常综合征中，移植后环磷酰胺联合抗胸腺细胞球蛋白作为移植物抗宿主病预防。
Acta Haematol. 2021;144(1):66-73. doi: 10.1159/000507536. Epub 2020 May 19.
6
Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome.异基因造血干细胞移植治疗骨髓增生异常综合征后无移植物抗宿主病、无复发生存。
Biol Blood Marrow Transplant. 2019 Jan;25(1):63-72. doi: 10.1016/j.bbmt.2018.08.004. Epub 2018 Aug 10.
7
Allogeneic hematopoietic cell transplantation with double alkylating agents containing reduced-intensity conditioning for patients ⩾60 years with advanced AML/MDS.对于年龄≥60岁的晚期急性髓系白血病/骨髓增生异常综合征患者，采用含双烷化剂的减低强度预处理进行异基因造血细胞移植。
Leukemia. 2016 Dec;30(12):2426-2429. doi: 10.1038/leu.2016.248. Epub 2016 Aug 30.
8
Allogeneic Stem Cell Transplantation for Patients with Lower-Risk Myelodysplastic Syndrome.异体造血干细胞移植治疗低危骨髓增生异常综合征。
Biol Blood Marrow Transplant. 2020 Nov;26(11):2047-2052. doi: 10.1016/j.bbmt.2020.07.018. Epub 2020 Jul 24.
9
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.采用基于 FLAMSA 的大剂量序贯预处理方案对高危骨髓增生异常综合征或继发性急性髓系白血病患者进行 upfront 同种异体造血干细胞移植。
Biol Blood Marrow Transplant. 2012 Mar;18(3):466-72. doi: 10.1016/j.bbmt.2011.09.006. Epub 2011 Sep 29.
10
[Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].[减低强度预处理异基因造血干细胞移植治疗骨髓增生异常综合征的研究进展 - 综述]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Aug;16(4):969-74.

引用本文的文献

1
Prevalence and outcome of VEXAS syndrome in unrelated hematopoietic cell transplantation for bone marrow failure.骨髓衰竭非亲缘造血细胞移植中VEXAS综合征的患病率及结局
Clin Exp Med. 2025 Aug 22;25(1):300. doi: 10.1007/s10238-025-01832-7.
2
Real-world outcomes of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome at a tertiary referral centre.三级转诊中心的液泡、E1酶、X连锁、自身炎症性、体细胞综合征的真实世界结局。
Br J Haematol. 2025 May 13;207(1):265-9. doi: 10.1111/bjh.20153.
3
Efficacy and safety profile of biotechnological agents and Janus kinase inhibitors in VEXAS syndrome: data from the international AIDA Network VEXAS registry.
生物技术药物和 Janus 激酶抑制剂在 VEXAS 综合征中的疗效和安全性概况：来自国际 AIDA 网络 VEXAS 登记处的数据。
Front Pharmacol. 2025 Feb 19;16:1462254. doi: 10.3389/fphar.2025.1462254. eCollection 2025.
4
Allogenic haematopoietic stem cell transplantation in VEXAS: A review of 33 patients.异基因造血干细胞移植治疗 VEXAS 综合征：33 例患者的回顾性研究。
Clin Rheumatol. 2024 Nov;43(11):3565-3575. doi: 10.1007/s10067-024-07160-7. Epub 2024 Sep 30.
5
Role of allogeneic hematopoietic cell transplantation in VEXAS syndrome.异基因造血细胞移植在 VEXAS 综合征中的作用。
Ann Hematol. 2024 Nov;103(11):4427-4436. doi: 10.1007/s00277-024-05942-2. Epub 2024 Aug 22.
6
A Rare Case of Bacterial Meningitis Caused by Hematogenous Spread of Vancomycin-Resistant in an Immunocompromised Patient.免疫功能低下患者中耐万古霉素菌血行播散致细菌性脑膜炎1例罕见病例
Case Rep Infect Dis. 2024 Jul 25;2024:2193650. doi: 10.1155/2024/2193650. eCollection 2024.
7
VEXAS syndrome.VEXAS综合征
Int J Hematol. 2024 May 31. doi: 10.1007/s12185-024-03799-9.
8
Successful treatment with fludarabine and cyclophosphamide in a VEXAS syndrome patient with associated myelodysplastic syndrome: a case report and systematic review.氟达拉滨和环磷酰胺成功治疗一名合并骨髓增生异常综合征的VEXAS综合征患者：病例报告及系统评价
Front Oncol. 2024 Apr 11;14:1383730. doi: 10.3389/fonc.2024.1383730. eCollection 2024.
9
Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study.佩格司他单抗治疗阵发性睡眠性血红蛋白尿症成年患者的安全性和疗效：48 周 307 例开放标签扩展研究。
Adv Ther. 2024 May;41(5):2050-2069. doi: 10.1007/s12325-024-02827-8. Epub 2024 Apr 4.
10
Autoimmunity and Autoinflammation: Relapsing Polychondritis and VEXAS Syndrome Challenge.自身免疫与自身炎症：复发性多软骨炎与 VEXAS 综合征的挑战。
Int J Mol Sci. 2024 Feb 13;25(4):2261. doi: 10.3390/ijms25042261.